Entia Biosciences, Inc. operates as a biotechnology company. The company is headquartered in Sherwood, Oregon. The company went IPO on 2007-11-01. The firm also develops and markets health-related nutraceuticals and cosmeceuticals. ErgoD2 is a pharmaceutical-grade organic compound created from whole foods that contain the micro-nutrients L-ergothioneine, an amino acid that has a transporter (SLC22A4) in every human being, and vitamin D2. ErgoD2 improves iron homeostasis and mitigates iron-related disorders presenting in anemia, chronic kidney disease and select neurodegenerative diseases. The firm's ErgoD2 formulations utilize organically cultivated specialty mushrooms available from various domestic and international suppliers. These mushroom-based products are generally regarded as safe (GRAS). The firm's market and scientific research has identified mushroom species and suppliers to provide the nutritional profiles for its ErgoD2 formulations.